A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once‐daily injection in patients with well‐controlled type 2 diabetes. (23rd March 2015)

• Record Type: Journal Article
• Authors: Inoue, Yuichiro; Nakamura, Akinobu; Kondo, Yoshinobu; Hamano, Kumiko; Satoh, Shinobu; Terauchi, Yasuo
• Is Part Of: Journal of clinical pharmacology. Volume 55:Number 7(2015:Jul.)
• Page Start: 831
• Page End: 838
• Publication Date: 2015-03-23
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.483
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph483-sec-0001" sec-type="section"> <p>This study aimed to compare the efficacy and safety of liraglutide versus insulin detemir plus sitagliptin in Japanese patients with type 2 diabetes treated with a basal‐bolus insulin regimen. In this multicenter, open‐label trial, 90 patients whose diabetes had been controlled well or moderately (glycated hemoglobin [HbA_1c] ≤ 7.3%) with basal‐bolus insulin regimen were randomly assigned to a liraglutide group or a detemir group and were followed up for 24 weeks. The primary end point was HbA_1c change from baseline to 24 weeks. Of the 90 enrolled patients, 82 completed this trial. At 24 weeks, the mean changes in HbA_1c from baseline were 0.1% ± 0.9% versus 0.3% ± 0.8% in the liraglutide versus detemir groups, respectively (<italic>P</italic> = .46). The "overall" satisfaction score for the Diabetes Treatment Satisfaction Questionnaire changed from 25.2 ± 7.4 to 29.9 ± 5.3 (<italic>P </italic>&lt; .001) and from 26.4 ± 6.1 to 28.3 ± 6.4 (<italic>P</italic> = .12) in the liraglutide and detemir groups, respectively. Although the mean change difference in HbA_1c between both groups was not significant, switching from a basal‐bolus insulin regimen to liraglutide once daily improved patient satisfaction levels without loss of glycemic control.</p> </sec> </abstract>